CYP2J2 Gene

HGNC Family	Cytochrome P450s (CYP)
Name	cytochrome P450, family 2, subfamily J, polypeptide 2
Description	This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is thought to be the predominant enzyme responsible for epoxidation of endogenous arachidonic acid in cardiac tissue. Multiple transcript variants have been found for this gene. [provided by RefSeq, Jan 2016]
Summary	{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n Cytochrome P450 2J2 (CYP2J2) is a multifunctional epoxygenase highly expressed in the cardiovascular system and several other tissues, where it catalyzes the conversion of arachidonic acid into epoxyeicosatrienoic acids (EETs). These lipid mediators play an important role in modulating vascular tone, inflammation, and cellular survival. In the heart, CYP2J2‐derived EETs enhance postischemic recovery and protect against myocardial injury by stimulating mitochondrial ATP‐sensitive potassium channels and activating MAPK and cyclic AMP–dependent pathways, thereby improving contractile function and resisting stress‐induced apoptosis."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": " Moreover, CYP2J2 activity appears to promote beneficial metabolic effects, as its products activate nuclear receptors such as PPARα that improve insulin sensitivity and contribute to the preservation of cardiac energy homeostasis in diabetic cardiomyopathy."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "3"}]}, {"type": "t", "text": ""}]}, {"type": "t", "text": "\n \n "}, {"type": "p", "children": [{"type": "t", "text": "\n In addition to its cardioprotective functions, CYP2J2 has been implicated in other pathophysiological processes. For instance, elevated expression of CYP2J2 in various cancer tissues and hematologic malignancies correlates with increased EET production that can promote tumor cell proliferation, migration, invasion, and resistance to apoptosis."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "5"}]}, {"type": "t", "text": " This pro-tumorigenic role is further modulated posttranscriptionally by microRNAs such as let-7b, which, when downregulated, allow for higher CYP2J2 protein levels and enhanced tumor aggressiveness."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "7"}]}, {"type": "t", "text": ""}]}, {"type": "t", "text": "\n \n "}, {"type": "p", "children": [{"type": "t", "text": "\n CYP2J2 also contributes to drug metabolism. It participates in the first-pass biotransformation of compounds such as astemizole, with its activity in the small intestine affecting the systemic availability of certain therapeutics."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "8"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n \n "}, {"type": "p", "children": [{"type": "t", "text": "\n Genetic variation in the CYP2J2 gene further influences its function and is linked to cardiovascular risk. Promoter polymorphisms such as G-50T have been associated with altered enzyme expression, lower EET formation, and an increased risk of coronary artery disease and hypertension."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "9", "end_ref": "11"}]}, {"type": "t", "text": " In endothelial and monocyte/macrophage cells, CYP2J2-generated EETs also function as endogenous anti-inflammatory mediators—limiting NF-κB signaling, reducing cytokine release, and ultimately protecting vascular integrity."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "12"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n \n "}, {"type": "p", "children": [{"type": "t", "text": "\n Finally, structural and mechanistic studies have provided insights into CYP2J2’s substrate specificity and inhibitory interactions, which are important for designing selective inhibitors both to modulate its activity therapeutically and to better understand its diverse roles in cardiovascular physiology, cancer, and drug metabolism."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "14"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n \n "}, {"type": "p", "children": [{"type": "t", "text": "\n In summary, CYP2J2 plays a central role in producing EETs that confer cardioprotection, regulate vascular inflammation, influence metabolic homeostasis, and even modulate tumor biology and drug disposition. Its activity and regulation—subject to genetic variability and posttranscriptional modulation—represent promising targets for therapeutic intervention in cardiovascular disease, metabolic disorders, and cancer."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}, {"type": "fg_f", "ref": "9"}, {"type": "fg_f", "ref": "5"}, {"type": "fg_f", "ref": "8"}, {"type": "fg_f", "ref": "10"}, {"type": "fg_f", "ref": "12"}, {"type": "fg_f", "ref": "3"}, {"type": "fg_f", "ref": "7"}, {"type": "fg_f", "ref": "15"}, {"type": "fg_f", "ref": "2"}, {"type": "fg_f", "ref": "11"}, {"type": "fg_f", "ref": "13"}]}, {"type": "t", "text": "\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "John Seubert, Baichun Yang, J Alyce Bradbury, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Circ Res (2004)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1161/01.RES.0000139436.89654.c8"}], "href": "https://doi.org/10.1161/01.RES.0000139436.89654.c8"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15256482"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15256482"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Yong-Fu Xiao, Qingen Ke, John M Seubert, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Enhancement of cardiac L-type Ca2+ currents in transgenic mice with cardiac-specific overexpression of CYP2J2."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Mol Pharmacol (2004)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1124/mol.104.004150"}], "href": "https://doi.org/10.1124/mol.104.004150"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15361551"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15361551"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Jessica A Wray, Mary C Sugden, Darryl C Zeldin, et al. "}, {"type": "b", "children": [{"type": "t", "text": "The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "PLoS One (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1371/journal.pone.0007421"}], "href": "https://doi.org/10.1371/journal.pone.0007421"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19823578"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19823578"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Rui Li, Xizhen Xu, Chen Chen, et al. "}, {"type": "b", "children": [{"type": "t", "text": "CYP2J2 attenuates metabolic dysfunction in diabetic mice by reducing hepatic inflammation via the PPARγ."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Am J Physiol Endocrinol Metab (2015)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1152/ajpendo.00118.2014"}], "href": "https://doi.org/10.1152/ajpendo.00118.2014"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "25389363"}], "href": "https://pubmed.ncbi.nlm.nih.gov/25389363"}]}, {"type": "r", "ref": 5, "children": [{"type": "t", "text": "Jian-Gang Jiang, Yao-Gui Ning, Chen Chen, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Cytochrome p450 epoxygenase promotes human cancer metastasis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Res (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1158/0008-5472.CAN-06-3643"}], "href": "https://doi.org/10.1158/0008-5472.CAN-06-3643"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17638876"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17638876"}]}, {"type": "r", "ref": 6, "children": [{"type": "t", "text": "Chen Chen, Xin Wei, Xiaoquan Rao, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Pharmacol Exp Ther (2011)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1124/jpet.110.174805"}], "href": "https://doi.org/10.1124/jpet.110.174805"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "21030485"}], "href": "https://pubmed.ncbi.nlm.nih.gov/21030485"}]}, {"type": "r", "ref": 7, "children": [{"type": "t", "text": "Fuqiong Chen, Chen Chen, Shenglan Yang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Let-7b inhibits human cancer phenotype by targeting cytochrome P450 epoxygenase 2J2."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "PLoS One (2012)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1371/journal.pone.0039197"}], "href": "https://doi.org/10.1371/journal.pone.0039197"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "22761738"}], "href": "https://pubmed.ncbi.nlm.nih.gov/22761738"}]}, {"type": "r", "ref": 8, "children": [{"type": "t", "text": "Shigeki Matsumoto, Tomoe Hirama, Tsutomu Matsubara, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Drug Metab Dispos (2002)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1124/dmd.30.11.1240"}], "href": "https://doi.org/10.1124/dmd.30.11.1240"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "12386130"}], "href": "https://pubmed.ncbi.nlm.nih.gov/12386130"}]}, {"type": "r", "ref": 9, "children": [{"type": "t", "text": "Martin Spiecker, Harald Darius, Thomas Hankeln, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Circulation (2004)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1161/01.CIR.0000143832.91812.60"}], "href": "https://doi.org/10.1161/01.CIR.0000143832.91812.60"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15466638"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15466638"}]}, {"type": "r", "ref": 10, "children": [{"type": "t", "text": "Lorraine M King, James V Gainer, Gloria L David, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pharmacogenet Genomics (2005)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1097/01213011-200501000-00002"}], "href": "https://doi.org/10.1097/01213011-200501000-00002"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15864120"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15864120"}]}, {"type": "r", "ref": 11, "children": [{"type": "t", "text": "Alexey V Polonikov, Vladimir P Ivanov, Maria A Solodilova, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A common polymorphism G-50T in cytochrome P450 2J2 gene is associated with increased risk of essential hypertension in a Russian population."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Dis Markers (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1155/2008/626430"}], "href": "https://doi.org/10.1155/2008/626430"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18219097"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18219097"}]}, {"type": "r", "ref": 12, "children": [{"type": "t", "text": "Jonas Bystrom, Jessica A Wray, Mary C Sugden, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Endogenous epoxygenases are modulators of monocyte/macrophage activity."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "PLoS One (2011)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1371/journal.pone.0026591"}], "href": "https://doi.org/10.1371/journal.pone.0026591"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "22028915"}], "href": "https://pubmed.ncbi.nlm.nih.gov/22028915"}]}, {"type": "r", "ref": 13, "children": [{"type": "t", "text": "Karni S Moshal, Darryl C Zeldin, Srinivas D Sithu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NF-kappabeta in hyperhomocysteinemia."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Cell Physiol (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/jcp.21356"}], "href": "https://doi.org/10.1002/jcp.21356"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18181170"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18181170"}]}, {"type": "r", "ref": 14, "children": [{"type": "t", "text": "Weihua Li, Yun Tang, Hong Liu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Probing ligand binding modes of human cytochrome P450 2J2 by homology modeling, molecular dynamics simulation, and flexible molecular docking."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Proteins (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/prot.21778"}], "href": "https://doi.org/10.1002/prot.21778"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18004755"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18004755"}]}, {"type": "r", "ref": 15, "children": [{"type": "t", "text": "Florian Herse, Babbette Lamarca, Carl A Hubel, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Cytochrome P450 subfamily 2J polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Circulation (2012)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1161/CIRCULATIONAHA.112.127340"}], "href": "https://doi.org/10.1161/CIRCULATIONAHA.112.127340"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "23155181"}], "href": "https://pubmed.ncbi.nlm.nih.gov/23155181"}]}]}]}
Synonyms	CYPIIJ2, CPJ2
Proteins	CP2J2_HUMAN
NCBI Gene ID	1573
API
Download Associations
Predicted Functions
Co-expressed Genes
Expression in Tissues and Cell Lines

Functional Associations

CYP2J2 has 5,843 functional associations with biological entities spanning 9 categories (molecular profile, organism, functional term, phrase or reference, chemical, disease, phenotype or trait, structural feature, cell line, cell type or tissue, gene, protein or microRNA, sequence feature) extracted from 115 datasets.

Click the + buttons to view associations for CYP2J2 from the datasets below.

If available, associations are ranked by standardized value

Harmonizome 3.0

CYP2J2 Gene

Functional Associations

Please acknowledge the Harmonizome in your publications by citing the following reference(s):

	Dataset	Summary
	Allen Brain Atlas Adult Human Brain Tissue Gene Expression Profiles	tissues with high or low expression of CYP2J2 gene relative to other tissues from the Allen Brain Atlas Adult Human Brain Tissue Gene Expression Profiles dataset.
	Allen Brain Atlas Adult Mouse Brain Tissue Gene Expression Profiles	tissues with high or low expression of CYP2J2 gene relative to other tissues from the Allen Brain Atlas Adult Mouse Brain Tissue Gene Expression Profiles dataset.
	Allen Brain Atlas Aging Dementia and Traumatic Brain Injury Tissue Sample Gene Expression Profiles	tissue samples with high or low expression of CYP2J2 gene relative to other tissue samples from the Allen Brain Atlas Aging Dementia and Traumatic Brain Injury Tissue Sample Gene Expression Profiles dataset.
	Allen Brain Atlas Developing Human Brain Tissue Gene Expression Profiles by Microarray	tissue samples with high or low expression of CYP2J2 gene relative to other tissue samples from the Allen Brain Atlas Developing Human Brain Tissue Gene Expression Profiles by Microarray dataset.
	Allen Brain Atlas Developing Human Brain Tissue Gene Expression Profiles by RNA-seq	tissue samples with high or low expression of CYP2J2 gene relative to other tissue samples from the Allen Brain Atlas Developing Human Brain Tissue Gene Expression Profiles by RNA-seq dataset.
	Allen Brain Atlas Prenatal Human Brain Tissue Gene Expression Profiles	tissues with high or low expression of CYP2J2 gene relative to other tissues from the Allen Brain Atlas Prenatal Human Brain Tissue Gene Expression Profiles dataset.
	Biocarta Pathways	pathways involving CYP2J2 protein from the Biocarta Pathways dataset.
	BioGPS Cell Line Gene Expression Profiles	cell lines with high or low expression of CYP2J2 gene relative to other cell lines from the BioGPS Cell Line Gene Expression Profiles dataset.
	BioGPS Human Cell Type and Tissue Gene Expression Profiles	cell types and tissues with high or low expression of CYP2J2 gene relative to other cell types and tissues from the BioGPS Human Cell Type and Tissue Gene Expression Profiles dataset.
	Carcinogenome Chemical Perturbation Carcinogenicity Signatures	small molecule perturbations changing expression of CYP2J2 gene from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.
	CCLE Cell Line Gene CNV Profiles	cell lines with high or low copy number of CYP2J2 gene relative to other cell lines from the CCLE Cell Line Gene CNV Profiles dataset.
	CCLE Cell Line Gene Expression Profiles	cell lines with high or low expression of CYP2J2 gene relative to other cell lines from the CCLE Cell Line Gene Expression Profiles dataset.
	CellMarker Gene-Cell Type Associations	cell types associated with CYP2J2 gene from the CellMarker Gene-Cell Type Associations dataset.
	ChEA Transcription Factor Binding Site Profiles	transcription factor binding site profiles with transcription factor binding evidence at the promoter of CYP2J2 gene from the CHEA Transcription Factor Binding Site Profiles dataset.
	ChEA Transcription Factor Targets	transcription factors binding the promoter of CYP2J2 gene in low- or high-throughput transcription factor functional studies from the CHEA Transcription Factor Targets dataset.
	ChEA Transcription Factor Targets 2022	transcription factors binding the promoter of CYP2J2 gene in low- or high-throughput transcription factor functional studies from the CHEA Transcription Factor Targets 2022 dataset.
	CM4AI KOLF21J CRISPRi Gene Perturbation Atlas	gene perturbations changing expression of CYP2J2 gene from the CM4AI KOLF21J CRISPRi Gene Perturbation Atlas dataset.
	CMAP Signatures of Differentially Expressed Genes for Small Molecules	small molecule perturbations changing expression of CYP2J2 gene from the CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.
	COMPARTMENTS Curated Protein Localization Evidence Scores	cellular components containing CYP2J2 protein from the COMPARTMENTS Curated Protein Localization Evidence Scores dataset.
	COMPARTMENTS Curated Protein Localization Evidence Scores 2025	cellular components containing CYP2J2 protein from the COMPARTMENTS Curated Protein Localization Evidence Scores 2025 dataset.
	COMPARTMENTS Text-mining Protein Localization Evidence Scores	cellular components co-occuring with CYP2J2 protein in abstracts of biomedical publications from the COMPARTMENTS Text-mining Protein Localization Evidence Scores dataset.
	COMPARTMENTS Text-mining Protein Localization Evidence Scores 2025	cellular components co-occuring with CYP2J2 protein in abstracts of biomedical publications from the COMPARTMENTS Text-mining Protein Localization Evidence Scores 2025 dataset.
	COSMIC Cell Line Gene CNV Profiles	cell lines with high or low copy number of CYP2J2 gene relative to other cell lines from the COSMIC Cell Line Gene CNV Profiles dataset.
	COSMIC Cell Line Gene Mutation Profiles	cell lines with CYP2J2 gene mutations from the COSMIC Cell Line Gene Mutation Profiles dataset.
	CTD Gene-Chemical Interactions	chemicals interacting with CYP2J2 gene/protein from the curated CTD Gene-Chemical Interactions dataset.
	CTD Gene-Disease Associations	diseases associated with CYP2J2 gene/protein from the curated CTD Gene-Disease Associations dataset.
	DepMap CRISPR Gene Dependency	cell lines with fitness changed by CYP2J2 gene knockdown relative to other cell lines from the DepMap CRISPR Gene Dependency dataset.
	DGIdb Drug Targets 2026	interacting drugs for CYP2J2 protein from the DGIdb Drug Targets 2026 dataset.
	DISEASES Experimental Gene-Disease Association Evidence Scores 2025	diseases associated with CYP2J2 gene in GWAS datasets from the DISEASES Experimental Gene-Disease Assocation Evidence Scores 2025 dataset.
	DISEASES Text-mining Gene-Disease Association Evidence Scores	diseases co-occuring with CYP2J2 gene in abstracts of biomedical publications from the DISEASES Text-mining Gene-Disease Assocation Evidence Scores dataset.
	DISEASES Text-mining Gene-Disease Association Evidence Scores 2025	diseases co-occuring with CYP2J2 gene in abstracts of biomedical publications from the DISEASES Text-mining Gene-Disease Assocation Evidence Scores 2025 dataset.
	DisGeNET Gene-Disease Associations	diseases associated with CYP2J2 gene in GWAS and other genetic association datasets from the DisGeNET Gene-Disease Associations dataset.
	DisGeNET Gene-Phenotype Associations	phenotypes associated with CYP2J2 gene in GWAS and other genetic association datasets from the DisGeNET Gene-Phenoptype Associations dataset.
	DrugBank Drug Targets	interacting drugs for CYP2J2 protein from the curated DrugBank Drug Targets dataset.
	ENCODE Histone Modification Site Profiles	histone modification site profiles with high histone modification abundance at CYP2J2 gene from the ENCODE Histone Modification Site Profiles dataset.
	ENCODE Transcription Factor Binding Site Profiles	transcription factor binding site profiles with transcription factor binding evidence at the promoter of CYP2J2 gene from the ENCODE Transcription Factor Binding Site Profiles dataset.
	ENCODE Transcription Factor Targets	transcription factors binding the promoter of CYP2J2 gene in ChIP-seq datasets from the ENCODE Transcription Factor Targets dataset.
	ESCAPE Omics Signatures of Genes and Proteins for Stem Cells	PubMedIDs of publications reporting gene signatures containing CYP2J2 from the ESCAPE Omics Signatures of Genes and Proteins for Stem Cells dataset.
	GAD Gene-Disease Associations	diseases associated with CYP2J2 gene in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset.
	GAD High Level Gene-Disease Associations	diseases associated with CYP2J2 gene in GWAS and other genetic association datasets from the GAD High Level Gene-Disease Associations dataset.